• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.

机构信息

Faculty of Medicine, University of Southampton, Southampton, UK.

Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.

出版信息

Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.

DOI:10.1038/s41375-023-02048-y
PMID:37794101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10624636/
Abstract

From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resistance, relapse or progression. Our scientific and clinical knowledge underpinning these requirements continues to evolve, as do laboratory methods and technologies. The European LeukemiaNet convened an expert panel to critically consider the current status of genetic laboratory approaches to help diagnose and manage CML patients. Our recommendations focus on current best practice and highlight the strengths and pitfalls of commonly used laboratory tests.

摘要

从实验室角度来看，有效管理慢性髓性白血病（CML）患者需要准确诊断、评估预后标志物、连续评估残留疾病水平以及调查耐药、复发或进展的可能原因。支持这些需求的我们的科学和临床知识在不断发展，实验室方法和技术也是如此。欧洲白血病网召集了一个专家小组，对当前的遗传实验室方法进行了批判性的考虑，以帮助诊断和管理 CML 患者。我们的建议侧重于当前的最佳实践，并强调了常用实验室检测的优势和缺陷。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/fd7c1344c723/41375_2023_2048_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/ed2fda570546/41375_2023_2048_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/3c4603e0aa03/41375_2023_2048_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/b6c5426e4414/41375_2023_2048_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/8f4233d120cc/41375_2023_2048_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/a1460df59731/41375_2023_2048_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/07216d041b03/41375_2023_2048_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/fd7c1344c723/41375_2023_2048_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/ed2fda570546/41375_2023_2048_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/3c4603e0aa03/41375_2023_2048_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/b6c5426e4414/41375_2023_2048_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/8f4233d120cc/41375_2023_2048_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/a1460df59731/41375_2023_2048_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/07216d041b03/41375_2023_2048_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b2/10624636/fd7c1344c723/41375_2023_2048_Fig7_HTML.jpg

相似文献

1
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。
Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.
2
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?从2013年到2020年欧洲白血病网关于慢性髓性白血病治疗的建议：这7年有哪些变化？
Expert Rev Hematol. 2020 Oct;13(10):1035-1038. doi: 10.1080/17474086.2020.1813564. Epub 2020 Sep 8.
3
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
4
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗停药后，我如何处理慢性髓性白血病复发问题。
Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19.
5
Best Practices in Chronic Myeloid Leukemia Monitoring and Management.慢性髓性白血病监测与管理的最佳实践
Oncologist. 2016 May;21(5):626-33. doi: 10.1634/theoncologist.2015-0337. Epub 2016 Mar 31.
6
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.酪氨酸激酶抑制剂治疗慢性髓性白血病患者的 BCR-ABL 激酶结构域突变分析：欧洲白血病网络专家组的建议。
Blood. 2011 Aug 4;118(5):1208-15. doi: 10.1182/blood-2010-12-326405. Epub 2011 May 11.
7
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.新型复合突变导致慢性髓性白血病对多种酪氨酸激酶抑制剂耐药的发现及蛋白建模研究。
Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3517-3526. doi: 10.31557/APJCP.2020.21.12.3517.
8
Treatment and molecular monitoring update in chronic myeloid leukemia management.慢性髓性白血病管理中的治疗与分子监测进展
Ann Biol Clin (Paris). 2017 Apr 1;75(2):129-145. doi: 10.1684/abc.2017.1233.
9
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.在异基因移植前患有费城染色体阳性白血病且存在BCR-ABL激酶突变的患者，主要会以相同的突变形式复发。
Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9. doi: 10.1016/j.bbmt.2014.09.012. Epub 2014 Oct 6.
10
Molecular Quantification and Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study.分子定量和突变检测作为慢性髓性白血病患者临床管理的重要工具：来自巴西单中心研究的结果。
Int J Mol Sci. 2023 Jun 14;24(12):10118. doi: 10.3390/ijms241210118.

引用本文的文献

1
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.2025年欧洲白血病网慢性髓性白血病管理建议
Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02664-w.
2
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.真实世界中慢性髓系白血病根据基线风险和一线治疗的结局：来自意大利网络/CML校园的数据。
Cancer. 2025 Jul 1;131(13):e35963. doi: 10.1002/cncr.35963.
3
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis.

本文引用的文献

1
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.FISH 阴性 BCR::ABL1 阳性 e19a2 慢性髓性白血病：最隐匿的插入。
BMC Med Genomics. 2023 Jul 26;16(1):172. doi: 10.1186/s12920-023-01607-7.
2
Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.在资源有限的环境下，对接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者进行多重 PCR 检测 BCR::ABL1 的预后相关截止值的评估。
Ann Hematol. 2023 Jul;102(7):1723-1729. doi: 10.1007/s00277-023-05254-x. Epub 2023 May 22.
3
阿伐替尼作为慢性髓性白血病二线或二线以上治疗方案治疗患者的疗效和安全性：一项系统评价与荟萃分析
Ther Adv Hematol. 2025 Jun 10;16:20406207251342203. doi: 10.1177/20406207251342203. eCollection 2025.
4
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.未达到深度分子反应的慢性髓性白血病患者的预后：来自GIMEMA实验室网络慢性髓性白血病网络数据库的结果
Am J Hematol. 2025 Aug;100(8):1467-1470. doi: 10.1002/ajh.27733. Epub 2025 Jun 5.
5
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.ABL1酪氨酸激酶的结构与动力学及其在慢性髓性白血病中的重要作用
Arch Pharm (Weinheim). 2025 May;358(5):e70005. doi: 10.1002/ardp.70005.
6
Chronic myeloid leukemia with the e13a3 atypical fusion gene: A case report.伴有e13a3非典型融合基因的慢性髓性白血病：一例报告
Oncol Lett. 2025 Apr 28;29(6):319. doi: 10.3892/ol.2025.15065. eCollection 2025 Jun.
7
Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives.通过下一代测序对急性和慢性白血病进行基因分型：当前见解与未来展望
Hematol Rep. 2025 Mar 28;17(2):18. doi: 10.3390/hematolrep17020018.
8
Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration.利用下一代测序推进慢性髓性白血病研究：潜在益处、局限性及未来临床整合
Hum Genet. 2025 May;144(5):481-503. doi: 10.1007/s00439-025-02745-x. Epub 2025 Apr 21.
9
Prognostic scoring systems in chronic myeloid leukaemia.慢性髓性白血病的预后评分系统
Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.
10
Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.博纳吐单抗联合奥雷巴替尼及同期鞘内化疗成功治疗慢性髓性白血病复发伴中枢神经系统原始细胞危象：病例报告及文献综述
Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06351-9.
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
阿西替尼单药治疗至少接受过两种 TKI 治疗的无 BCR::ABL1 T315I 突变的 CML-CP 患者：4 年的 1 期安全性和疗效结果。
Leukemia. 2023 May;37(5):1048-1059. doi: 10.1038/s41375-023-01860-w. Epub 2023 Mar 22.
4
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.阿西替尼对比博舒替尼治疗至少两种酪氨酸激酶抑制剂治疗后的慢性期慢性髓性白血病：ASCEMBL 的长期随访。
Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30.
5
Measurable residual disease in chronic myeloid leukemia.慢性髓性白血病的可测量残留病。
Haematologica. 2022 Dec 1;107(12):2794-2809. doi: 10.3324/haematol.2022.281493.
6
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.慢性髓性白血病加速期和急变期的发病机制与管理
Leukemia. 2023 Jan;37(1):5-17. doi: 10.1038/s41375-022-01736-5. Epub 2022 Oct 29.
7
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.ASXL1 突变对慢性期慢性髓性白血病的预后影响。
Blood Cancer J. 2022 Oct 28;12(10):144. doi: 10.1038/s41408-022-00742-1.
8
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.二次融合蛋白作为慢性髓性白血病中 BCR::ABL1 激酶非依赖性耐药的机制。
Br J Haematol. 2023 Feb;200(3):323-328. doi: 10.1111/bjh.18515. Epub 2022 Oct 20.
9
Impact of emerging ACA on survival in chronic myeloid leukemia (CML).新型美国临床肿瘤学会（ACA）对慢性髓性白血病（CML）生存率的影响。
Leukemia. 2022 Oct;36(10):2544-2547. doi: 10.1038/s41375-022-01681-3. Epub 2022 Aug 23.
10
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.利用液滴数字 PCR 技术检测慢性髓性白血病中第二代酪氨酸激酶抑制剂耐药的 BCR::ABL1 激酶结构域突变。
Leukemia. 2022 Sep;36(9):2250-2260. doi: 10.1038/s41375-022-01660-8. Epub 2022 Jul 30.